Latest Insider Transactions at Ionis Pharmaceuticals Inc (IONS)
This section provides a real-time view of insider transactions for Ionis Pharmaceuticals Inc (IONS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IONIS PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IONIS PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2024
|
Spencer R Berthelsen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+8.93%
|
$560,000
$35.53 P/Share
|
|
May 09
2024
|
Joseph H Wender Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
16,000
+11.11%
|
$560,000
$35.53 P/Share
|
|
May 03
2024
|
Joseph Klein Iii Director |
SELL
Open market or private sale
|
Indirect |
6,000
-41.42%
|
$252,000
$42.76 P/Share
|
|
Apr 16
2024
|
Brian Birchler EVP, Corp and Development Ops |
SELL
Open market or private sale
|
Direct |
905
-1.92%
|
$37,105
$41.66 P/Share
|
|
Apr 16
2024
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,006
-16.95%
|
$164,246
$41.6 P/Share
|
|
Apr 15
2024
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+3.83%
|
-
|
|
Apr 15
2024
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,838
+31.44%
|
-
|
|
Feb 29
2024
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
383
+0.48%
|
$13,022
$34.42 P/Share
|
|
Feb 29
2024
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Other acquisition or disposition
|
Direct |
604
+1.32%
|
$20,536
$34.42 P/Share
|
|
Feb 29
2024
|
Richard S Geary EVP, Chief Development Officer |
BUY
Other acquisition or disposition
|
Direct |
604
+0.68%
|
$20,536
$34.42 P/Share
|
|
Feb 29
2024
|
Brett P Monia Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
538
+0.31%
|
$18,292
$34.42 P/Share
|
|
Feb 29
2024
|
Eric Swayze EVP Research |
BUY
Other acquisition or disposition
|
Direct |
605
+1.7%
|
$20,570
$34.42 P/Share
|
|
Feb 16
2024
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
387
-0.22%
|
$17,028
$44.49 P/Share
|
|
Feb 02
2024
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,853
-2.29%
|
$90,797
$49.52 P/Share
|
|
Feb 02
2024
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
SELL
Open market or private sale
|
Direct |
2,125
-5.6%
|
$104,125
$49.6 P/Share
|
|
Feb 02
2024
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,961
-2.2%
|
$98,050
$50.04 P/Share
|
|
Feb 02
2024
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
2,125
-2.24%
|
$104,125
$49.54 P/Share
|
|
Feb 02
2024
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
23,501
-11.89%
|
$1,151,549
$49.37 P/Share
|
|
Feb 02
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
1,961
-3.87%
|
$96,089
$49.67 P/Share
|
|
Feb 02
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
2,071
-3.99%
|
$101,479
$49.59 P/Share
|
|
Feb 02
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
1,907
-5.26%
|
$93,443
$49.56 P/Share
|
|
Feb 01
2024
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,609
+4.27%
|
-
|
|
Feb 01
2024
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
BUY
Grant, award, or other acquisition
|
Direct |
4,140
+9.84%
|
-
|
|
Feb 01
2024
|
Richard S Geary EVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,820
+4.1%
|
-
|
|
Feb 01
2024
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,140
+4.17%
|
-
|
|
Feb 01
2024
|
Brett P Monia Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,788
+10.94%
|
-
|
|
Feb 01
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,820
+7.02%
|
-
|
|
Feb 01
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
4,033
+7.21%
|
-
|
|
Feb 01
2024
|
Eric Swayze EVP Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,715
+9.3%
|
-
|
|
Jan 31
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
10,773
-24.89%
|
$560,196
$52.0 P/Share
|
|
Jan 25
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
6,450
-12.11%
|
$328,950
$51.75 P/Share
|
|
Jan 25
2024
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,285
-1.48%
|
$116,535
$51.75 P/Share
|
|
Jan 17
2024
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
SELL
Open market or private sale
|
Direct |
5,564
-14.13%
|
$278,200
$50.42 P/Share
|
|
Jan 17
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
7,744
-12.7%
|
$387,200
$50.42 P/Share
|
|
Jan 17
2024
|
Brian Birchler EVP, Corp and Development Ops |
SELL
Open market or private sale
|
Direct |
4,497
-9.16%
|
$224,850
$50.42 P/Share
|
|
Jan 17
2024
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
7,338
-7.91%
|
$366,900
$50.42 P/Share
|
|
Jan 17
2024
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
8,683
-8.72%
|
$434,150
$50.42 P/Share
|
|
Jan 17
2024
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
32,059
-17.22%
|
$1,602,950
$50.42 P/Share
|
|
Jan 17
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
5,482
-10.28%
|
$274,100
$50.42 P/Share
|
|
Jan 17
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Indirect |
9
-9.57%
|
$450
$50.42 P/Share
|
|
Jan 17
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
6,296
-12.7%
|
$314,800
$50.42 P/Share
|
|
Jan 17
2024
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Indirect |
564
-25.59%
|
$28,200
$50.42 P/Share
|
|
Jan 17
2024
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,460
-10.24%
|
$73,000
$50.42 P/Share
|
|
Jan 17
2024
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,745
-8.02%
|
$337,250
$50.42 P/Share
|
|
Jan 16
2024
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
BUY
Exercise of conversion of derivative security
|
Direct |
15,062
+27.67%
|
-
|
|
Jan 16
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,641
+25.28%
|
-
|
|
Jan 16
2024
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
12,080
+19.75%
|
-
|
|
Jan 16
2024
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,852
+17.62%
|
-
|
|
Jan 16
2024
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,487
+18.42%
|
-
|
|
Jan 16
2024
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
68,084
+26.78%
|
-
|